Norfloxacin HCl 400 mg Tablets Require Granulation Endpoint Control Below 1.5× Baseline Torque

In high-speed rotary press operations, norfloxacin HCl crystalline powder presents two processing barriers: needle-shaped crystal morphology and poor flow. Carr's compressibility index for unprocessed API typically lies between 25% and 35%, confirming poor to very poor flow characteristics. Bulk density ranges from 0.3 to 0.5 g/cm³ across supplier batches. These properties render direct compression of a 400 mg strength tablet impractical on production-speed presses. Wet granulation with aqueous povidone K30 at 2–4% w/w (dry granulate basis) addresses both flow and compressibility simultaneously. The granulation endpoint on a high-shear granulator is determined by impeller power-consumption plateau rather than fixed mixing time. Endpoint corresponds to a torque increase not exceeding 1.5× the dry-mix baseline. Impeller tip speed of 5–10 m/s and chopper speed of 1500–3000 rpm represent typical operating ranges for this formulation class. Over-granulation above the power threshold produces dense granules with impaired disintegration and prolonged dissolution lag time. Wet mass moisture content of 3–4% w/w at discharge is dried in a fluid bed dryer at 50–60°C inlet air temperature. Residual moisture of 1.5–2.5% w/w is confirmed by loss-on-drying. The dried granulate is milled through a 1.0–2.0 mm screen and sieved. The fraction retained between 180 μm and 850 μm should exceed 80% w/w. Fines below 180 μm are held below 15% w/w to prevent capping. Lubrication with magnesium stearate 0.5–1.0% w/w is conducted in a tumble blender at 10–15 rpm for 3–5 minutes. Lubrication beyond 5 minutes forms a hydrophobic film on granule surfaces that retards dissolution in acidic medium. Compression on a 16–24 station rotary press at 15–25 kN yields tablets with crushing strength of 80–120 N. Friability per USP <1216> should not exceed 1.0%. Disintegration time per USP <701> in 0.1 N HCl at 37 ± 2°C should not exceed 15 minutes. Dissolution testing per USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl requires NLT 80% (Q) release within 30 minutes. Crospovidone 4–6% w/w is incorporated intragranularly for matrix disruption upon contact with dissolution medium. Croscarmellose sodium 2–4% w/w may be added extragranularly for faster disintegration. Commercial line failure modes include picking and sticking on tooling when compression force exceeds 25 kN and moisture content exceeds 2.5% w/w. Capping occurs when fines below 180 μm exceed 15% w/w. Batch-to-batch variance in API crystal habit from different suppliers requires re-optimization of binder concentration and granulation endpoint for each new lot.

When Roller Compaction Replaces Wet Granulation for Norfloxacin HCl at Drug Loads Above 30% w/w

Roller compaction is evaluated when solvent-free manufacturing is mandated or when water exposure poses stability concerns for co-processed excipients. The process is viable at norfloxacin HCl drug loads up to 60% w/w. Above 60% w/w, compact quality degrades and fines generation increases sharply. Roll pressure is maintained between 30 and 80 kN. Roll speed is set at 5–15 rpm. Gap width is controlled at 1.5–3.0 mm. The resulting ribbons achieve density of 0.8–1.0 g/cm³. Ribbons are milled through a 0.8–1.2 mm screen. The milled granulate is sieved to remove fines below 90 μm. Pre-compression force on the tablet press is set at 3–5 kN. Main compression force is maintained at 10–20 kN. Tablet hardness of 60–90 N is typical for roller-compacted material. The formulation includes crospovidone 4–6% w/w as disintegrant and microcrystalline cellulose as filler/binder. Magnesium stearate lubrication is limited to 0.5% w/w for no more than 3 minutes of blending time. Prolonged lubricant exposure is particularly problematic for roller-compacted granules due to their higher specific surface area relative to wet granulated material. Dissolution performance of roller-compacted tablets is generally comparable to wet granulation when disintegration is controlled within 15 minutes. Published comparative dissolution data for norfloxacin HCl roller compaction versus wet granulation is limited. Process-specific validation is mandatory. Ribbon porosity below 30%, corresponding to over-compaction above 80 kN roll force, leads to prolonged disintegration and dissolution failure. Residual moisture is maintained below 2.0% w/w. Roller compaction is particularly suitable for norfloxacin HCl formulations containing hygroscopic fillers such as mannitol, where aqueous granulation would produce partial dissolution and subsequent re-crystallization artifacts. The zwitterionic structure of norfloxacin with pKa values of approximately 6.3 and 8.4 contributes to pH-dependent material properties that affect ribbon formation and subsequent milling behavior.

Directly filling the needle-shaped norfloxacin HCl API into hard gelatin capsules produces fill-weight variation exceeding USP <905> acceptance limits because the powder fails to flow uniformly through dosing disc or dosator nozzles. Slugging on a rotary press at 15–20 kN followed by dry screening through a 12-mesh (1.4 mm) sieve yields granulate acceptable for automated filling. The fill blend is composed of lactose monohydrate as filler, pregelatinized starch 5–10% w/w as binder/disintegrant, and magnesium stearate 0.5–0.75% w/w as lubricant. Crospovidone 2–4% w/w may be added to improve disintegration. Capsule filling is performed on dosing-disc machines operating at 60,000–120,000 capsules per hour for commercial batches. Size 0 capsules accommodate 200 mg strength with fill weight of 300–350 mg. Size 1 capsules accommodate 400 mg strength with fill weight of 450–550 mg. Content uniformity per USP <905> requires an acceptance value not exceeding 15 across 10 individual dosage units. Disintegration of capsules per USP <701> should not exceed 15 minutes in 0.1 N HCl. Dissolution testing follows USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl with the same Q = 80% at 30 minutes as tablet presentations. Hard gelatin capsule shells typically demonstrate moisture content of 13–16% w/w. Norfloxacin HCl exhibits minimal hygroscopicity, reducing cross-shell moisture migration risk during shelf storage. Packaging in aluminum-PVC/PVDC blister or HDPE bottles with silica gel desiccant is standard. Published stability data for 24–36 months under ICH long-term conditions (25 ± 2°C / 60 ± 5% RH) generally support storage in USP tight containers.

What Limits Sedimentation Volume and Dose Uniformity in Reconstituted Norfloxacin HCl Oral Suspension Granules?

For pediatric and geriatric populations requiring dose flexibility, dry powder granules of norfloxacin HCl for oral suspension are packaged as amber glass bottles or foil-laminated sachets. Reconstitution with purified water to a total volume of 60 mL or 100 mL is performed at the point of dispensing. The granule formulation includes sucrose or mannitol as bulk diluent. Xanthan gum 0.2–0.4% w/w is added as suspending agent. Sodium carboxymethylcellulose 0.3–0.6% w/w serves as secondary rheology modifier. Citric acid/sodium citrate buffer maintains a reconstituted pH of 4.5–5.5. The pH buffer is critical because norfloxacin HCl solubility decreases sharply above pH 6.0. Unbuffered suspensions in neutral water may produce dissolution incompatibility and unacceptable bioavailability. Antimicrobial preservation is provided by methylparaben 0.1% w/w and propylparaben 0.01–0.02% w/w. Preservative efficacy testing conforms to Ph. Eur. 5.1.3 and FDA 21 CFR 201.100 requirements for oral liquids. Granulate particle size distribution targets sieve fractions between 180 μm and 710 μm for ease of wetting upon reconstitution. Dose uniformity testing per USP <905> on the reconstituted suspension after shaking requires an acceptance value not exceeding 15 across 10 withdrawn aliquots. Sedimentation volume (F value) measured after 24 hours should remain above 0.8. The reconstituted suspension stability is typically limited to 7–14 days at 2–8°C. After this window, preservative efficacy and pH drift may fall outside specification. A shake-before-use label instruction is mandatory. Published zeta potential values for norfloxacin HCl suspension formulations are limited. Flocculation behavior is controlled empirically by adjusting suspending agent concentration rather than electrostatic stabilization. The amber glass container provides photoprotection because norfloxacin HCl undergoes photodegradation upon prolonged light exposure in aqueous solution.

As a parenteral presentation, injectable norfloxacin HCl solution for intravenous infusion is prepared in water for injection at 2 mg/mL or 4 mg/mL in markets where this presentation is approved. Published data for this specific configuration is limited. pH adjustment using dilute hydrochloric acid or sodium hydroxide targets a final pH of 3.5–4.5. Below pH 3.0, acid-catalyzed hydrolysis of the piperazine ring occurs. Above pH 5.5, the drug precipitates due to reduced ionization of the carboxylic acid group. Osmolality is adjusted to 280–320 mOsm/kg using sodium chloride or dextrose 5% w/v as isotonicity agent. Terminal sterilization is performed by autoclaving at 121°C for 15–20 minutes. Norfloxacin HCl demonstrates adequate thermal stability under these conditions. Photodegradation requires protection from light during manufacturing and storage. Amber glass ampoules or Type I borosilicate glass vials are used as primary containers. The solution is stable for 24–36 months when stored at controlled room temperature with light exclusion. Compatibility testing with common IV diluents is mandatory. Dilution to concentrations below 1 mg/mL in neutral pH diluents can produce precipitation. Binary admixture with alkaline drugs is contraindicated because pH elevation above 5.5 precipitates the free base. Infusion rate for a 400 mg dose is typically 60 minutes. Endotoxin testing per USP <85> with acceptance limit not exceeding 0.5 EU/mg is mandatory for parenteral grade material. Particulate matter per USP <788> with not more than 6000 particles ≥10 μm and not more than 600 particles ≥25 μm per container applies. Sterility testing per USP <71> is conducted on 20 units. The API must meet endotoxin limit not exceeding 0.5 EU/mg and bioburden not exceeding 100 CFU/g prior to sterile filtration or terminal sterilization. Residual solvents per USP <467> and ICH Q3C apply depending on manufacturing route. Elemental impurities per USP <232>/<233> with ICH Q3D limits apply. Norfloxacin HCl typically requires Class 1, 2A, and 2B elemental assessment. Aseptic processing is an alternative when terminal sterilization is not possible due to container-closure system incompatibility. In that case, sterile filtration through 0.22 μm membrane filters is performed prior to filling in a Class A (ISO 5) environment.